Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
A Trial of Carboxypeptidase-G2 (CPDG2) for the Management of Patients with Intrathecal Methotrexate Overdose Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on A Trial of Carboxypeptidase-G2 (CPDG2) for the Management of Patients with Intrathecal Methotrexate Overdose conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A Trial of Carboxypeptidase-G2 (CPDG2) for the Management of Patients with Intrathecal Methotrexate Overdose Clinical research trials and A Trial of Carboxypeptidase-G2 (CPDG2) for the Management of Patients with Intrathecal Methotrexate Overdose healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including A Trial of Carboxypeptidase-G2 (CPDG2) for the Management of Patients with Intrathecal Methotrexate Overdose. A Trial of Carboxypeptidase-G2 (CPDG2) for the Management of Patients with Intrathecal Methotrexate Overdose Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a A Trial of Carboxypeptidase-G2 (CPDG2) for the Management of Patients with Intrathecal Methotrexate Overdose clinical trial. Test subjects oftentimes recieve the best healthcare possible for their A Trial of Carboxypeptidase-G2 (CPDG2) for the Management of Patients with Intrathecal Methotrexate Overdose condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.

Home > "A" Clinical Trials Conditions > A Trial of Carboxypeptidase-G2 (CPDG2) for the Management of Patients with Intrathecal Methotrexate Overdose

A Trial of Carboxypeptidase-G2 (CPDG2) for the Management of Patients with Intrathecal Methotrexate Overdose



A Trial of Carboxypeptidase-G2 (CPDG2) for the Management of Patients with Intrathecal Methotrexate Overdose

For Condition: Leukemia,Peripheral Nervous System Disease
Status: Recruiting
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: Nonrandomized study. Intrathecal Methotrexate Rescue. Carboxypeptidase-G2, CPDG2, NSC-641273.
Details: Methotrexate is the most widely used intrathecal antineoplastic agent. Accidental IT overdose, usually the result of inadvertent IT injection of a higher dose intended for systemic administration, can produce severe and frequently lethal toxicity. Current therapeutic approaches are invasive and often ineffective. Carboxypeptidase-G2 (CPDG2), an enzyme that hydrolyzes the C-terminal glutamate residue from MTX, may potentially serve as a rescue agent for patients suffering from potentially lethal IT MTX overdoses. This trial will study the ability of a single IT injection of CPDG2 to rescue patients with IT MTX overdose.
Eligibility:
Study Type:  Interventional, Treatment, Safety
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Any patient who receives an IT overdose of MTX greater than or equal to 100 mg will be eligible for the study. Written informed consent. EXCLUSION CRITERIA: Patients who have previously developed an anaphylactic reaction prior to CPDG(2) administration are ineligible. There will be no exclusions based on concurrent therapy.
Total Enrollment: 10

Location and Contact Information:

National Cancer Institute (NCI) *Recruiting*
Bethesda,  Maryland,  20892
United States
Recruiting Clinical  Support Center/NCI 1-888-624-1937


Additional Information:
Study ID Numbers:  920137;  92-C-0137
Study Start Date: March 28, 1992
Record last reviewed: February 1, 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001299

Other Leukemia Studies:
1. VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas

2. Phase I Study of Intrathecal Topotecan

3. T-Cell-Depleted Allogeneic Stem Cell Transplantation Followed By Treated Donor T Cells After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

4. Study of @neWorld: A Virtual Community for Children With Cancer

5. Sirolimus in Preventing Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Related Studies:

Other Leukemia Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials

A Trial of Carboxypeptidase-G2 (CPDG2) for the Management of Patients with Intrathecal Methotrexate Overdose
Modify your Search

  Other Leukemia Clinical Trials
  Other Maryland Clinical Trials
  Other Bethesda Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103